MUC1 and cancer: While the explorations of effector functions in this manuscript were limited to cells of hematopoietic origin, the additional distribution of overexpressed MUC1 across various solid tumor types accounts for its presence in up to 80% of human cancers [66,67] and continues to make MUC1 an attractive target for immunotherapy.